GSK (NYSE:GSK) said on Tuesday that it will acquire clinical-stage biopharmaceutical company Aiolos Bio for a $1B upfront payment and up to $400M on achieving certain regulatory milestones.

Chris So Wai-yin feels the pressure of taking a talented first-starter to the races, but said he was not about to rush things with his gun three-year-old Aiolos. So will unveil the son of Super ...

GSK has taken another step towards rebuilding its respiratory pipeline with a $1.4 billion agreement to buy Aiolos Bio and its lead drug AIO-001 for asthma and other indications. The deal ...

GSK has agreed to acquire the asthma drug specialist Aiolos Bio for a deal worth up to $1.4bn, as it aims to strengthen its respiratory and inflammatory asset pipeline. GSK will pay $1bn upfront ...